Advanced hepatocellular carcinoma treated by a combination of sorafenib and radiotherapy

被引：0
|
作者：
Yang, Bi-Ling [1 ]
Yeh, Chun [1 ]
Hsu, Chung-Te [1 ]
Chang, Tien-Yu [2 ]
Wang, Chung-Yih [3 ]
机构：
[1] Cheng Hsin Gen Hosp, Dept Internal Med, Dept Gastroenterol, Taipei, Taiwan
[2] Cheng Hsin Gen Hosp, Dept Radiol, Taipei, Taiwan
[3] Cheng Hsin Gen Hosp, Dept Radiat Oncol, Taipei, Taiwan
来源：
ADVANCES IN DIGESTIVE MEDICINE | 2014年 / 1卷 / 01期
关键词：
Hepatocellular carcinoma; Sorafenib; Radiotherapy;
D O I：
10.1016/j.aidm.2014.01.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Advanced hepatocellular carcinoma has a poor therapeutic outcome and treatment options are limited. Sorafenib, an orally active multikinase inhibitor, is the only systemic drug that has been shown to provide survival benefits in randomized control studies. However, the gains in survival are modest and new treatment strategies are needed. We report here the case of a patient with advanced hepatocellular carcinoma who had an impressive response to a combination of sorafenib and radiotherapy. The treatment was well tolerated with no unexpected toxicities. Post-treatment imaging showed a satisfactory partial response with regression of the tumor by more than 50%. Copyright (C) 2014, The Gastroenterological Society of Taiwan and The Digestive Endoscopy Society of Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
引用
收藏
页码：25 / 29
页数：5
相关论文
共 50 条
  • [21] The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib
    Sarpel, Umut
    Spivack, John H.
    Berger, Yaniv
    Heskel, Marina
    Aycart, Samantha N.
    Sweeney, Robert
    Edwards, Martin P.
    Labow, Daniel M.
    Kim, Edward
    HPB, 2016, 18 (05) : 411 - 418
  • [22] Targeted genome profiling in patients with advanced hepatocellular carcinoma treated with sorafenib
    Kang, Wonseok
    Kim, Kyung
    Lee, Joon Hyeok
    Lim, Ho Yeong
    Park, Woong-Yang
    Lee, Jeeyun
    Paik, Yong Han
    CANCER RESEARCH, 2017, 77
  • [23] Analysis of postprogression survival of patients with advanced hepatocellular carcinoma treated with sorafenib
    Wada, Y.
    Takami, Y.
    Matsushima, H.
    Ryu, T.
    Mikagi, K.
    Saitsu, H.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S630 - S631
  • [24] Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
    Otsuka, Taiga
    Eguchi, Yuichiro
    Kawazoe, Seiji
    Yanagita, Kimihiko
    Ario, Keisuke
    Kitahara, Kenji
    Kawasoe, Hiroaki
    Kato, Hiroyuki
    Mizuta, Toshihiko
    HEPATOLOGY RESEARCH, 2012, 42 (09) : 879 - 886
  • [25] Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib
    Chen, D.
    Zhao, P.
    Li, S. -Q.
    Xiao, W. -K.
    Yin, X. -Y.
    Peng, B. -G.
    Liang, L. -J.
    EJSO, 2013, 39 (09): : 974 - 980
  • [26] Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
    Antonelli, G.
    Gigante, E.
    Iavarone, M.
    Begini, P.
    Sangiovanni, A.
    Iannicelli, E.
    Biondetti, P.
    Pellicelli, A. M.
    Miglioresi, L.
    Marchetti, P.
    Lampertico, P.
    Marignani, M.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 14 - 14
  • [27] Sorafenib in Advanced Hepatocellular Carcinoma Reply
    Llovet, Josep M.
    Bruix, Jordi
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23): : 2498 - 2499
  • [28] Oral sorafenib for advanced hepatocellular carcinoma
    Nature Clinical Practice Oncology, 2006, 3 (12): : 648 - 649
  • [29] Sorafenib for the treatment of advanced hepatocellular carcinoma
    Connock, M.
    Round, J.
    Bayliss, S.
    Tubeuf, S.
    Greenheld, W.
    Moore, D.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 17 - 21
  • [30] Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
    Sanoff, Hanna K.
    Chang, YunKyung
    Lund, Jennifer L.
    O'Neil, Bert H.
    Dusetzina, Stacie B.
    ONCOLOGIST, 2016, 21 (09): : 1113 - 1120
12345